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Olfactory ensheathing cells show promise in preclinical animal models as a cell transplantation therapy for
repair of the injured spinal cord. This is a report of a clinical trial of autologous transplantation of olfactory
ensheathing cells into the spinal cord in six patients with complete, thoracic paraplegia.We previously reported
on the methods of surgery and transplantation and the safety aspects of the trial 1 year after transplantation.
Here we address the overall design of the trial and the safety of the procedure, assessed during a period of 3
years following the transplantation surgery. All patients were assessed at entry into the trial and regularly
during the period of the trial. Clinical assessments included medical, psychosocial, radiological and neurological,
as well as specialized tests of neurological and functional deficits (standard American Spinal Injury Association
and Functional Independence Measure assessments).Quantitative test included neurophysiological tests of sen-
sory and motor function below the level of injury.The trial was a Phase I/IIa design whose main aim was to test
the feasibility and safety of transplantation of autologous olfactory ensheathing cells into the injured spinal cord
in human paraplegia. The design included a control group who did not receive surgery, otherwise closely
matched to the transplant recipient group. This group acted as a control for the assessors, who were blind to
the treatment status of the patients.The control group also provided the opportunity for preliminary assess-
ment of the efficacy of the transplantation.There were no adverse findings 3 years after autologous transplanta-
tion of olfactory ensheathing cells into spinal cords injured at least 2 years prior to transplantation.The magnetic
resonance images (MRIs) at 3 years showed no change from preoperative MRIs or intervening MRIs at 1 and 2
years, with no evidence of any tumour of introduced cells and no development of post-traumatic syringomyelia
or other adverse radiological findings.There were no significant functional changes in any patients and no neuro-
pathic pain. In one transplant recipient, there was an improvement over 3 segments in light touch and pin prick
sensitivity bilaterally, anteriorly and posteriorly. We conclude that transplantation of autologous olfactory
ensheathing cells into the injured spinal cord is feasible and is safe up to 3 years of post-implantation, however,
this conclusion should be considered preliminary because of the small number of trial patients.
Keywords: human; transplantation; spinal cord injury; paraplegia
Abbreviations: ASIA=American Spinal Injury Association Impairment Scale; COVS=Clinical OutcomeVariables Scale;
FDI=first dorsal interoseous; FIM=Functional Independence Measure; IADL=Instrumental Activities of Daily Living;
MRI=Magnetic Resonance Imaging; SSEP=somatosensory evoked potentials;TMS=transcranial magnetic stimulation;
ZPP=zone of partial preservation
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Olfactory ensheathing cells are specialized glia that
surround the olfactory nerve fascicles as they project from
the sensory epithelium to the olfactory bulb (Doucette,
1990). They have generated considerable interest as
candidates for cell transplantation therapies for repair of
spinal cord injury after numerous preclinical studies
(Raisman, 2001; Mackay-Sim, 2005; Richter and Roskams,
2007). They are accessible in human via biopsy through the
external naris (Feron et al., 1998, 2005; Bianco et al., 2004).
In 2002, we initiated a single-blinded, controlled trial to
establish the safety and feasibility of intraspinal transplanta-
tion of autologous olfactory ensheathing cells in human
spinal cord injury. An initial report described the surgical
procedure and safety outcome of the trial after 1 year
(Feron et al., 2005). This report describes in detail the
design of the trial and describes the results of clinical,
psychosocial, neurological and neurophysiological assess-
ments that were made every 3/6 months over the 3 years
following cell transplantation.
In considering the design of a Phase I/IIa trial of a cell
therapy in spinal cord injury, several aspects were
paramount. Complete (American Spinal Injury Association
Impairment Scale Grade A: ASIA A), thoracic level of injury
was chosen to minimize the risk of loss of useful function
above the site of injury. Choice of patients who had
completed at least 6 months post injury would provide a
homogeneous group with stable neurological and functional
baselines from which to assess changes due to treatment.
Psychosocial health and stability was considered important
to counter potentially unrealistic expectations of clinical
trial outcomes. It would also increase the likelihood of
retaining the patients for the long follow-up period of the
trial. Long-term follow-up was considered important for
assessing risks associated with the development of cysts,
syringomyelia or transplanted cell over-growth, or the
development of neuropathic pain. Repeated assessment
raised important issues of assessor variability and bias.
Variability was controlled by using the same assessors
throughout. Bias was controlled by having a control group
of patients, with the assessors blinded to treatment group.
The presence of a control group then raised the possibility
of obtaining preliminary data on the therapeutic effect of
cell transplantation, although this was not the primary aim
of this trial.
Methods
Overview
Patients were recruited after the review of medical records and
personal or telephone interviews. From over 600 such interviews,
12 persons were selected who initially fitted the inclusion criteria.
These people took part in the intensive selection process in which
they were interviewed and educated about the nature of the trial
including aims, risks and design. These people were assessed
medically and radiologically and undertook the initial 2h
psychosocial assessment by psychiatrist and social worker. This
assessment process selected six patients for the trial who agreed to
take part as transplant recipients or as non-operated controls after
being thoroughly informed of the trial and its attendant risks. The
transplant recipients were counselled to expect no clinical benefit
and they accepted that risk for altruistic reasons. Strict criteria
were applied in order to select patients who were as homogeneous
as possible within and between groups. Recruitment took place
over a 2-year period so that the trial took 5 years to complete.
After recruitment, the patients were assessed to establish
baseline measures. All transplant patients then received a nasal
biopsy from which olfactory ensheathing cells were grown for
autologous transplantation into the injured thoracic spinal cord of
the transplant recipient group. Regular assessments then followed
for 3 years. Patients were not instructed to follow any particular
exercise regime and all undertook their usual daily activities.
Throughout the trial, at each assessment from the initial selection
through to completion, a rehabilitation physician with extensive
experience in management of people with spinal cord injury,
who was not blind to group status, acted as reviewing physician.
The reviewing physician conducted an independent neurological
examination of each patient at each assessment session. He exam-
ined each patient to monitor their health with the responsibility
to immediately notify the trial manager and ethics committees of
any adverse events, with the power to stop the trial.
The study was designed to maximize statistical power through
the selection of homogeneous patients groups, a within subjects
comparison (i.e. before and after), a non-transplanted control
group, a single blind assessment regime, the same assessors
throughout and a rigorous and long-term follow-up.
The trial was approved by the ethics committees of the Princess
Alexandra Hospital, Griffith University and Queensland University
of Technology, according to guidelines of the National Health and
Medical Research Council of Australia. The trial was approved by
the Therapeutic Goods Administration of Australia and accord-
ingly monitored by the responsible ethics committees.
Selection criteria
The primary inclusion criterion was a traumatic injury of the
thoracic spinal cord (T4–T10) occurring 6 months to 3 years prior
to enrolment in the trial, resulting in a sustained and complete
loss of sensory and motor function below the injury (ASIA
Category A, ‘ASIA A’ classification). Exclusion criteria included:
substance abuse, spinal vertebral instability, major concurrent
medical illness (e.g. carcinoma, auto-immune disease, diabetes
mellitus) and ASIA Impairment Scale category other than A.
Syringomyelia was also an exclusion criterion but an exemption
was made for a control patient with a stable syrinx. Patients with
major and current psychiatric illness, who had significant
traumatic brain injury associated with the spinal cord injury or
who were otherwise considered unable to provide fully informed
consent were also excluded. Additional selection was based on a
1-hour interview and psychosocial assessment performed by a
social worker and psychiatrist (Fronek, 2004). The initial interview
included an assessment of understanding of research project and
risk factors, evidence of patient’s ability to cope with a negative/
positive result, assessment of significant other/family’s attitude
towards research and possible negative result and other issues
raised during the interview. The purpose of the interview was
to select patients with a stable social and family background,
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probability of a change in function as a result of the trial, as well
as the remote possibility that the implant procedure may cause
deterioration in neurological function. This selection was con-
sidered necessary to reduce ‘false hope’ of recovery and to provide
the highest probability of compliance with the demands of the
trial over the 3-year assessment period.
Transplantation procedures
The nasal biopsy, olfactory ensheathing cell culture and surgical
procedures are fully described elsewhere (Feron et al., 2005). In
brief, biopsies were taken from the olfactory mucosa under general
anaesthesia and olfactory ensheathing cells were cultured from
these biopsies for 4–10 weeks. After appropriate tests for cell
sterility, they were transplanted into the injured spinal cord. A
laminectomy was performed and, following a durotomy, cells were
injected into the spinal cord at multiple sites throughout the
damaged cord and into the proximal and distal ends of the intact
cord. Transplantation and surgery were performed under micro-
scopic control and using a purpose-designed injector device
(Feron et al., 2005).
Initial and repeated assessments
All assessments were performed with the assessors blinded to the
group status of the patients. Before the assessments, the surgical
scar of transplant recipients was covered with a bandage and a
similar bandage was applied to the controls. Patients progressed
through the trial in pairs, each assessed in the same sessions.
Variability was reduced by the use of the same assessors
throughout the study, obviating any inter-observer variability.
Blinded assessors did not discuss the trial results with each other
and the results of their assessments were not collated until the end
of the trial. No results were revealed to patients or other trial team
members during the course of the trial.
Pre-operatively, the transplant recipients were assessed for
haematology, blood chemistry and urine microbiology and
screening for HIV and Hepatitis B and C status. They also
received chest and thoracic spine X-rays. They were examined by
the otorhinolaryngologist before olfactory tissue biopsy (Feron
et al., 1998). All patients had their sense of smell tested on
admission to the trial and 3 months later using a quantitative
olfactory test (Mackay-Sim et al., 2004).
Magnetic resonance imaging (MRI) undertaken on a 1.5 Tesla
instrument by the Radiology Department, Princess Alexandra
Hospital. MRI (T1-weighted with gadolinium and T2-weighted)
was performed after selection for inclusion into the trial and at
6 months, 1, 2 and 3 years.
The health of the patients was monitored by the reviewing
spinal injuries physician and a clinical nurse. The clinical nurse
took regular physical observations (blood pressure, temperature,
pulse respiration rate). The spinal injuries physician undertook a
physical examination, assessed anterior ASIA sensory level of
impairment, skin and bowel and bladder function. Health
assessments were made every 3 months.
Mental health was assessed by a psychiatrist and social worker
as part of the initial selection process and at each assessment point
throughout the trial (Fronek, 2004). The psychiatrist made a
clinical assessment of mental health status. The social worker took
a social history and history of injury that included: the
rehabilitation process, the adjustment to disability, current
social/legal/financial situation, current care needs and services,
pain and alcohol/drug use. Psychosocial assessments were made at
1 week, 1 month, 3 months, 6 months, 12 months and 3 years.
Clinical Outcome Variables Scale (COVS) assessment was
undertaken by an experienced spinal injuries physiotherapist
(Campbell and Kendall, 2003). COVS was performed by each
patient using standard instructions. If the patient felt unable to
perform a skill, a score of 1 was recorded. A video was taken of
each test completed by the patient. A second examiner was
employed to validate the scoring. No patient was able to perform
any of the ambulation items hence all these items were scored as
1. The physiotherapist also performed: respiratory function tests
(spirometry) in both supine and sitting positions; an assessment of
muscle tone and spasm using the Modified Ashworth Scale; a skin
examination and recording of bowel and bladder self-reports; and
ASIA classification of neurological function. Pain was assessed via
interview using an in-house multidisciplinary pain-assessment tool
that includes asking the patient to identify painful areas on the
body identified on a body chart, to describe the pain using
standard descriptors (burning, throbbing, sharp etc), and to
identify temporal aspects of pain. Patients rated pain ‘now’, ‘at its
worst’ and ‘average level’ and rated severity on a 10-point
numerical rating scale as recommended (Bryce et al., 2007).
An experienced spinal injuries occupational therapist undertook
the Functional Independence Measure (FIM), a battery of hand
function assessments, and Lawton’s Instrumental Activities of
Daily Living (IADL) (Lawton and Brody, 1969). The FIM and
IADL were completed via interview/report rather than direct
observation of skills. These assessments were made every 3
months.
A neurologist undertook an examination, independently of ASIA
examination, that included history, pin prick, motor assessment and
assessment of light touch and pin prick impairment level measured
fromthesternalnotchanteriorly andthespinousprocessposteriorly.
Another neurologist assessed somatosensory evoked potentials
(SSEP) evoked in the sensory cortex after electrical stimulation of
the sensory nerves in the legs. SSEP was the only assessment that was
not performed by the same person throughout the study. Three
assessors made these measurements. Neurological assessments were
made every 3 months.
A neurophysiologist performed transcranial magnetic stimula-
tion (TMS) of the motor cortex to evoke activity in the lower
limbs bilaterally (tibial anterior, vastus lateralis) using
both figure of eight and circular coils. The upper limbs served
as positive controls by evoking movement in the first dorsal
interoseous (FDI) muscles, stimulated with a figure of eight coil.
Stimulation intensity of the FDI was set at 10% greater than the
resting threshold for activation. Stimulation of the lower limb
muscles was performed at the same intensity as for the FDI
muscles and also at 90% and 100% of stimulator output. TMS
assessments were made every 6 months.
Results
Patients
Patients were males, aged 18–55 years, with the period since
their injury ranging from 18–32 months and were
neurologically stable (Table 1). All had ASIA A spinal
cord injury between T4 and T7 of traumatic aetiology with
no evidence of ongoing recovery of spinal cord function.
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Post-surgical recovery was unremarkable and there were no
adverse findings at 1 year, as described previously (Feron
et al., 2005). Olfactory function was not affected by nasal
biopsy, tested before biopsy and three months later with all
patients scoring in the normal range on this test (Mackay-
Sim et al., 2004; Hummel et al., 2007).
Independent medical conditions during
the trial
Transplant recipient 1 had a pre-existing bladder calculus
treated (cystoscopy and litholaplaxy) 4 months after cell
transplantation. Transplant recipient 3 was treated for
epididymo-orchitis 15 months after cell transplantation.
Control patient 3 was treated for pneumonia 3 months
after enrolling in trial.
Radiology
The radiological findings in the transplant recipients were
unchanged from the findings at 1 year post-transplantation
(Feron et al., 2005). As noted previously, only an extensive
increase in spinal cord volume would be detectable with the
1.5T MR imaging available, and none was seen at 1, 2 or 3
years post-transplantation. There were no adverse effects of
transplantation visible in any of the MRIs of the three
transplant recipients at any time (Fig. 1). The control
patients showed no change in MRI from baseline at entry
into the trial. There were no changes in the volume of the
cystic area at the injury site. In any patient, there was
neither syringomyelia nor pseudomeningocoele. No new
masses were visible in any of the MRI images at the
injection site or anywhere else in the neuraxis. The pre-
operative sagittal alignment of the spine was maintained
with no new external compression of the spinal cord.
Clinical assessment of transplant recipients
at 3 years post-transplantation
Clinical and neurological findings at 3 years post-trans-
plantation were unremarkable. There was no deterioration
in neurological or functional level in any of the patients.
There was no deterioration in sensory or motor function.
There was no worsening of respiratory function. None of
the patients experienced any new or additional neuropathic
pain. There was no worsening in the severity of spasticity in
any patients. Careful monitoring indicated that there was
no worsening of the conditions over the period of the trial.
Psychosocial assessments
There was no deterioration in psychosocial status and all
patients coped well. None of the patients had required any
additional or unplanned counselling regarding the trial.
There was no difference in psychosocial status between the
transplant recipients and the controls.
Table 1 ASIA Assessment: level of injury and zones of
partial preservation at baseline and 36 months
Patient
a Sex Age (years) Baseline
b 36 months
b
RLR L
T1 M 46 Level T7 T7 T7 T7
Z P P T 9T 8T 9 T 9
T2 M 30 Level T4 T4 T4 T4
Z P P T 5T 6T 5 T 5
T3 M 23 Level T3 T3 T3 T3
Z P P T 6T 6T 5 T 5
C1 M 18 Level T3 T3 T3 T3
ZPP 0 0 0 0
C2 M 55 Level T2 T2 T3 T3
Z P P T 4T 6T 4 T 4
C3 M 36 Level T4 T4 T3 T3
Z P P T 5T 5T 4 T 6
aT1^3: transplant recipients; C1^3: control patients,
bR:rightside;
L:lefts ide
Fig.1 Sagittal MR imaging of patients at 36 months after olfactory
ensheathing cell transplants. Patients1, 2 and 3 are shown as pairs
(A and B,C and D, E and F, respectively).On the left are
T1-weighted images with gadolinium contrast. On the right are
T2-weighted images. Patient 3 has two cylindrical metal cages
in the vertebral spaces, placed for treatment of the original
vertebral column trauma, seen as white artifacts prominent
in theT1-weighted image.
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There were small variations in the COVS scores of patients.
Table 2 shows the mean differences between baseline scores
and scores at 36 months. There was no improvement in any
of the subscales in either transplant recipients or controls.
Pain assessments
Most of the pain reported in the study was musculoskeletal
pain or surgical pain that resolved normally. One transplant
recipient had some neuropathic pain prior to enrolling in
the trial. There was no ongoing neuropathic pain associated
with the trial, with similar presentations by patients in both
groups.
Respiratory function tests
Respiratory function tests were included to monitor
respiratory status and to assist in detecting changes in
intercostal and abdominal muscle function. Respiratory
function was restricted as expected in patients with these
levels of spinal cord injury. There were no significant
changes in respiratory function over the course of the trial
and no effect of transplantation on respiratory function as
assessed by sitting and supine FEV1, FVC and FEV1/FVC
ratio.
Functional assessments
There were no significant changes over the trial period in
any of the measures of functional activity in daily life: FIM
(motor), FIM (cognition) and IADL (Table 3). There was
some variability noted in FIM locomotion scores where
individuals were required to rate the amount of assistance
they would require to go up and down a flight of 14 stairs.
The variability depended on how the person was feeling on
the day as to whether they would require one or two people
to help. Some of the variability on the IADL scale could be
attributed to changing functional skills irrespective of the
study. There was no effect of treatment on hand function:
hand grip (Jaymar dynamometer); pinch strength; coordi-
nation (Hole Peg test, Preston Grooved Pegboard test).
There was no effect of treatment on any of these tests as
demonstrated in Table 3, which shows mean group
differences between baseline and 36 month assessments.
ASIA assessments
There was no change in ASIA grade in any of the patients.
There were minor variations in the zone of partial
preservation (ZPP) for patients in both the control and
surgery groups evident at 3 years (Table 1), but there were
no consistent group differences. The motor and sensory
scales were considered separately. The scores for both upper
and lower motor scales remained the same for every
assessment during the 3 years of the trial. The scores were
universally 50 and 0 for each patient, for each assessment.
There were minor variations in the sensory scores for light
touch and for pin prick during the 3-year trial (Fig. 2).
These minor variations in scores were due to differences in
reported sensitivities close to the level of injury.
Neurological and neurophysiological
assessments
The light touch and pin prick assessments made by the
neurologist indicated significant variability in the transplant
group, compared to the control group. When transplant
recipient 1 was tested at 1 month, light touch and pin prick
sensitivity extended further caudally compared to the initial
measurements, on left and right sides and on front and
back skin surfaces. This increased sensitivity was main-
tained for the rest of the 36 months observation period
(Fig. 3). The extension of sensitivity in this Patient 1 was
also noted by the reviewing physician who noted an
Table 2 COVS: mean group differences between baseline
and 36 month tests
COVS: maximum score 7 per item Transplant Control
Mean SD Mean SD
1.Roll right/left side in bed 0.3 0.58 1.0 1.73
2.Get to a sitting position from
supine lying in bed
0.3 0.58 0.0 0.00
3. Sitting balance 0.7 0.58 0.0 0.00
4a. Horizontal transfer 0.3 0.58 0.3 0.58
4b.Vertical transfer 0.3 2.08 0.7 0.58
5. Performance of ambulation 0.0 0.00 0.0 0.00
6. Performance of ambulation with aids 0.0 0.00 0.0 0.00
7. Performance of ambulationçendurance 0.0 0.00 0.0 0.00
8. Performance of ambulationçvelocity 0.0 0.00 0.0 0.00
9. Performance of wheelchair mobility 0.0 0.00 0.3 0.58
10. Lt/Rt arm function 0.0 0.00 0.0 0.00
Table 3 Functional testing: mean group differences
between baseline and 36 month tests
Transplant Control
Mean SD Mean SD
FIMS motor (max. score: 91) 1.00 2.65 0.00 0.37
FIMS cognition (max. score: 35) 0.00 0.00 0.00 0.00
Lawton’s IADL (max. score: 16) 0.00 0.00 0.67 0.00
H a n df u n c t i o ng r i pL( k gf o r c e ) 3.57 4.70 0.05 4.44
Hand function grip R (kg force) 0.77 5.55 0.13 2.81
Hand function Palmar pinch L (kg force) 0.30 2.11 1.49 1.07
Hand function Palmar pinch R (kg force) 0.20 2.26 1.50 0.78
Hand function 3-point pinch L (kg force) 0.40 2.29 0.30 1.22
Hand function 3-point pinch R (kg force) 0.40 2.91 0.50 1.47
Hand function Lateral pinch L (kg force) 3.50 2.91 1.03 1.29
Hand function Lateral pinch R (kg force) 3.77 3.09 0.00 1.40
9H o l ep e gt e s tL( s e c ) 1.67 2.15 2.55 2.06
9H o l ep e gt e s tR( s e c ) 0 . 1 8 2 . 2 2 2.86 0.78
Preston grooved pegboard L (sec) 1.4 4 3.79 12.81 2.56
Preston grooved pegboard R (sec) 4.75 0.99 5.75 3.76
2380 Brain (2008),131, 2376^2386 A. Mackay-Sim et al.increase in light touch and pin prick sensitivity from T4 to
T10. Light touch and pin prick sensitivity did not change in
any of the other patients.
SSEPs were never evoked in any patient after electrical
stimulation of lower sensory nerves. Control stimulations to
upper limb sensory nerves reliably evoked SSEPs. TMS
never activated lower limb muscles for either group even
when stimulation was at 100% of coil intensity. The FDI
muscles were activated in both of the upper limbs and the
latency of activation remained constant for both experi-
mental and control groups across all assessments.
Discussion
There were no adverse findings 3 years after autologous
transplantation of olfactory ensheathing cells into the
injured spinal cords of patients whose spinal cord injuries
were incurred at least 2 years prior to transplantation. The
MRIs at 3 years showed no change from pre-operative
MRIs or intervening MRIs at 1 and 2 years, with no
evidence of any tumour or cyst of introduced cells and no
development of post-traumatic syringomyelia or other
adverse radiological findings. Similar stability in MRI
findings was observed in both groups of patients, transplant
recipients and controls. In most other measures, all patients
showed very stable outcomes from pre-operative through to
the final assessment at 3 years. The neurological assessment
revealed small improvements in light touch and pin prick
sensitivity in one transplant recipient anteriorly and
posteriorly. This increased extent of sensation was observed
at 1 month post-transplantation and remained for the rest
of the trial. The reviewing physician noted the increase in
sensitivity anteriorly in this patient but it was not noted by
the physiotherapist undertaking ASIA sensory assessment.
This suggests that the increased sensation was below
threshold for clinical assessment.
Trial de sign
This study, initiated in 2001, was a controlled, single-
blinded design which included a within-subjects compar-
ison. In most respects, this design conforms to the recent
recommendations of an international committee for the
design of clinical trials in spinal cord injury (Fawcett et al.,
2007; Lammertse et al., 2007; Steeves et al., 2007; Tuszynski
et al., 2007).
Thoracic injuries were preferred in this first trial to
minimize the risk of serious functional impairment should
the procedure lead to damage above the level of injury
(Tuszynski et al., 2007). A period of 6 months was chosen
in the present study to minimize the likelihood of
spontaneous recovery among the patients (Fawcett et al.,
2007). This choice of complete, thoracic injuries at 6
months was demonstrated to have the most statistical
power, requiring the fewest patients (Fawcett et al., 2007).
The planned size of the study was limited to a total of eight
patients by the hospital and university ethics committees.
The final size was limited by difficulties in recruitment due
to the relatively low frequency of thoracic level spinal cord
injury and the strict selection criteria.
The trial required repeated assessment of transplant
recipients for 3 years. A non-operated control group
provided a longitudinal comparison for the period of the
trial. This control group assisted in assessing the probability
of spontaneous recovery over the 3-year trial period.
Spontaneous recovery causing a change from initial ASIA
A grade may occur in up to 20% of persons when
reassessed at 1 year after diagnosis (Fawcett et al, 2007),
although the majority of persons with thoracic spinal cord
injury diagnosed ASIA A at 6 months will not change
further by 1 year (Fawcett et al., 2007). This was the
minimum period for inclusion in the present study.
Nonetheless, spontaneous recovery should not be disre-
garded because, at least after cervical injuries, 5.6% of
persons diagnosed ASIA A at 1 year had changed the grade
at 5 years (Fawcett et al., 2007). Functional improvement in
one individual was not recorded until after 5 years
(McDonald et al., 2002). Such statistics emphasize the
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Fig. 2 ASIA sensory scores during the period of the trial. (A)
Sensory scores for light touch in the transplant recipients
(closed symbols, lines) and Controls (open symbols, dotted lines).
(B) Pin prick scores for pin prick in the transplant recipients
(closed symbols, lines) and controls (open symbols, dotted lines).
Olfactory ensheathing cell transplants Brain (2008),131, 2376^2386 2381importance of a control comparison group. The statistics
also emphasize the importance of the period since the
injury in defining a stable pre-intervention baseline. Ideally,
a sham-surgical control is preferred but in this trial, the
risks associated with surgery raised significant ethical issues,
highlighting the difficulties of achieving the ‘best design’
versus what is both ethically acceptable and practical. In
addition, the surgical risks meant that the patients were not
randomized to treatment and control groups. The accep-
tance of the surgical risk acted as a selection criterion, such
that others agreed to act as controls, without wishing to be
part of the transplant group. With informed consent being
such an important part of the selection process, and with
the numbers of patients being limited by type of injury, it
then became impossible to randomize the selection process.
The resultant trial design thus reduced without eliminating,
all the sources of bias inherent in clinical trials (Lammertse
et al., 2007).
Blinded assessment is considered essential to eliminate
bias in clinical trials because of the qualitative nature of
clinical examinations (Lammertse et al., 2007). Assessor bias
was reduced in the present study by using the same
assessors throughout and by blinding them to patient
treatment. For clinical examinations, two assessors made
their assessments and reports independently and without
consulting the other. Another possible source of bias may
have been the necessary selection of highly motivated
patients who may have under-reported negative effects such
as pain, discomfort and psychological disappointment. The
presence or impact of such bias is unknown but in this and
future trials the inclusion of a similarly highly motivated
control may help reduce any effect of such bias.
Fig. 3 Changes in light touch and pin prick sensitivity during the period the trial.The graph shows the differences in location of sensitivity
to light touch and pin prick, anteriorly and posteriorly (8 measurements per patient) at baseline (0 months) and 3 years later (36 months).
The locations were measured in centimetres from the sternal notch (anteriorly) and spinous process (posteriorly).
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human trials (Lima et al., 2006) and animal studies
demonstrated the efficacy of whole olfactory lamina propria
(Lu et al., 2001, 2002), the present study used a purified
population of olfactory ensheathing cells (Bianco et al.,
2004) in order to reduce variability among the transplants.
Additionally, this was considered to reduce the probability
of adverse outcomes such as overgrowth of cells. Olfactory
mucosa, including lamina propria, contains many other cell
types including endothelium, fibroblasts and glandular cells
whose behaviour in the spinal cord are not known. Also
present are olfactory stem cells (Murrell et al., 2005), which
are efficacious after transplantation into the injured spinal
cord (Xiao et al., 2005) but their long-term proliferation
capacity is not defined. In contrast, olfactory ensheathing
cells cease proliferating after transplantation into the spinal
cord (Deng et al., 2006).
Long-term follow-up was considered a necessary part of
the design of any initial trial of the safety of olfactory
ensheathing cell transplantation. Although this procedure
was safe at 1 year (Feron et al., 2005), 3 years was
considered necessary to assess the possibility of the
development of tumour, cyst or syrinx at the site of
transplantation.
There is debate about the efficacy of exercise and
rehabilitation in improving outcomes after spinal cord
injury. Nonetheless, if neural circuits were rebuilt by an
intervention then it is reasonable to expect a better
functional outcome if the regenerating neuronal circuits
are active, as demonstrated after regeneration of optic
nerves in lizard (Beazley et al., 2003) and motor nerves
(Pavlov et al., 2008) but not mixed nerve (Sinis et al., 2008)
in rat. Appropriate exercise, when combined with olfactory
ensheathing cell transplantation significantly improved
motor function, compared to cell transplantation alone in
rat (Kubasak et al., 2008). The design of this trial did not
include exercise. Its primary goal was to test the safety of
the transplantation procedure over a 3-year period. For this
goal, patients were asked to report once in three months for
assessment during their already busy lives. In the trial
design, compliance for assessment of negative outcomes was
considered more important than exploring the effect of
exercise. In any case, the homes of the participants were
located in city and in country areas, some hundreds of
kilometres from the clinic, so application of a supervised
exercise regime would have been impractical.
Finally, this study was designed with an emphasis on the
psychosocial health of the patients, initially as part of the
selection process and subsequently as part of the assessment
of the outcomes of the trial. A stable psychosocial profile
was considered important because of the highly emotive
aspects of new experimental therapies in spinal cord injury
and the potential for unrealistic expectations of some
people with spinal cord injury. Fully informed patients were
chosen with little expectation of recovery through this trial.
This stability may have contributed to the retention of all
patients for the 3 year course of the trial, an essential
requirement for already small group numbers.
Outcome measures
Recent reviews discuss the strengths and weaknesses of
various outcome measures available and under develop-
ment for spinal cord injury (Bryce et al., 2007; Lam et al.,
2008; Steeves et al., 2007). Of those used here, the ASIA
scale measures neurological function and the FIM scale
measures useful functional ability. Although these may be
insensitive to small changes in physiology, which are of
interest scientifically, both scales are well validated and used
in clinics throughout the world. The ASIA scale is made up
of sensory and motor components and these are useful
measures of specific and smaller changes due to the
experimental treatment. The additional neurological assess-
ments in the present study indicate that more intense
investigations of light touch and pin prick can reveal small,
variable, sensory changes that are not obvious in a standard
ASIA examination. The FIM tool is a valid and reliable
instrument for functional independence of many patients,
including those with spinal cord injury (Ottenbacher et al.,
1996). This standard clinical tool was chosen to monitor
whether the cell transplantation procedure had an adverse
effect on functional independence. After the start of our
trial, a specialized instrument [Spinal Cord Independence
Measure (SCIM) II] was introduced for assessing functional
independence specifically after spinal cord injury (Catz
et al., 2001). The SCIM scale is still undergoing modifica-
tion (Catz et al., 2007) but future trials should consider
using it instead of FIM because of its specificity for spinal
cord injury which may make it sensitive to improvements
in function as a result of the intervention as demonstrated
by its ability to follow changes during the first year after
complete injury (Wirth et al., 2008). Future trials would
benefit from validated measures of pain assessment that are
now available (Bryce et al., 2007). The COVS is a mobility
scale that has construct validity for spinal cord rehabilita-
tion when its subscales are recognized (Campbell and
Kendall, 2003).
Future trials should consider including quantitative tests
of sensory function, developed recently, which can identify
small changes around the site of injury in complete thoracic
injuries although these need further validation for general
application (Savic et al., 2006, 2007). Such quantitative
measures may pick up small changes that will be important
scientifically, and will direct future trials, but unless the
changes are enough to alter clinical measures, such as ASIA
scores, they will not have much impact on the patient. The
present study included quantitative electrophysiological
assessments (somatosensory evoked potentials, transcranial
magnetic stimulation) for measurements of sensory and
motor function in the lower limbs. Assessment of thoracic
spinal cord function is noted as particularly problematic
(Steeves et al., 2007). In agreement with this, we initially
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tinued because of variability around the level of injury.
Recently, more fine grained and validated test tools and
protocols have become available for assessing thoracic
motor function (Ellaway et al., 2007), which may be
more appropriate for future trials when sub-clinical
outcome measures are required.
MR imaging provided a qualitative, clinical assessment of
the extent of injury and any changes during the course of
the trial. These images were taken at a clinical radiology
department with an instrument with 1.5T field-strength.
Clinical instruments with a field-strength of 3T are now
commonly available and these would provide better
resolution in future trials, perhaps combined with diffusion
tensor imaging (Ellingson et al., 2008), although such
quantitative analysis is yet to be validated in spinal cord
injury. For the moment MRI remains a qualitative measure
(Steeves et al., 2007). Higher resolution MRI may allow
detection of transplanted cells. Olfactory ensheathing cells
labelled with iron oxide paramagnetic particles are detect-
able with MRI and survive for at least 2 months after
transplantation into the spinal cord in rat (Dunning et al.,
2004; Lee et al., 2004). A limitation is that it is not possible
to distinguish the MRI signal of living transplanted cells
from dead cells or macrophage or microglia that may
phagocytose the label during an inflammatory process.
Clinical transplantation of olfactory tissues
A recent report described a clinical study of autologous
transplantation of olfactory mucosa in human spinal cord
injury (Lima et al., 2006). In seven patients, pieces of
olfactory mucosa were placed into the spinal cord after
removal of the scar tissue, at 6 months to 6.5 years post-
injury. Patients were assessed pre-operatively and followed
for 18 months post-operatively. The transplant procedure
was considered safe, with minimal adverse outcomes:
temporary pain for 2–3 months in the trunk and lower
limbs in two patients and the loss of sensory component of
the ASIA score in one patient. Six patients gained sensory
and/or motor function whereas one patient lost sensory
function but gained motor function as measured on
components of the ASIA scale. Two patients changed
their ASIA grade from A to C. Some patients improved
their bladder and bowel control. It was concluded that this
transplantation procedure was ‘fairly safe’ and ‘may
promote functional recovery’ (Lima et al., 2006). Another
report describes transplantation of fetal ‘olfactory ensheath-
ing cells’ into the injured spinal cord in 300 patients with
complete spinal cord injury (ASIA grade A) and incomplete
spinal cord injury (ASIA grade B–D) (Huang et al., 2006).
Although the cells were derived from the olfactory bulbs of
12- to 16-week-old human fetuses, their identity as
‘olfactory ensheathing cells’ was not demonstrated and
doubtful (Dobkin et al., 2006). These allograft transplants
were made without immune suppression and the patients
were followed for 2–8 weeks after transplantation.
There was apparently ‘no fever, spinal cord infection,
functional deterioration or mortality’ associated with the
procedure (Huang et al., 2006). Remarkably, 117 patients
were reported to improve their ASIA scores 2–8 weeks after
the procedure, most of whom began to improve within 2–3
days of the procedure (Huang et al., 2006). An independent
examination of seven patients who underwent the same
procedure concluded that ‘patients have encountered
serious medical complications and no lasting increase in
sensorimotor function or functional ability’ (Dobkin et al.,
2006). Neither of these previous studies was a controlled
clinical trial, raising questions about the validity of
conclusions of improved function. Patient function was
measured pre-operatively, providing a baseline with which
to compare post-operative function, but there was no
independent assessment of possible longitudinal changes,
assessed with a control group, nor was the assessment
blinded.
The current trial has raised no safety-related issues
resulting from transplantation of autologous olfactory
ensheathing cells into the injured human spinal cord,
either at the time of surgery or at any time during the
3-year follow-up period. Despite the careful design of this
trial, its findings must be considered preliminary because of
the small numbers of patients involved. The finding that
one transplant recipient had minor but measurable
improvement in sensation below the original level of
injury is noteworthy and encouraging for future trials.
The optimal timing for olfactory ensheathing cell trans-
plantation is unknown. Certainly delayed transplantations
of olfactory ensheathing cells are efficacious in rat models
(Lu et al., 2002; Keyvan-Fouladi et al., 2003; Plant et al.,
2003), but the maximum delay was only 1 month, rather
than 2 years. It is possible that earlier transplantations may
have a better chance of succeeding in humans.
The injured spinal cord is still changing in many patients
during the first year (Marino et al., 1999), and transplanta-
tion during this period may be more effective. Similarly,
with time, the function of spinal neuronal circuits degrade
caudal to the injury (Dietz and Muller, 2004) and earlier
intervention and/or exercise to maintain those circuits
(Dietz and Curt, 2006). Nevertheless, spinal neuronal
circuits may still retain the ability to recover after a long
time period, because 5.6% of patients who had neurologi-
cally complete injury at 1 year improved their ASIA grade
at 5 years (Kirshblum et al., 2004).
The primary aim of the present trial was to test safety,
rather than efficacy. For the latter, such trials will require
larger numbers in order to have appropriate power to
overcome the increased variability due to spontaneous
recovery (Fawcett et al., 2007). Recruitment and selection
of appropriate patients into larger trials will be a challenge,
as our experience has demonstrated, and is likely to
require national and/or international multi-centre
collaborations.
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